ALPHATUDE V2.0 21May2025

  • Research type

    Research Study

  • Full title

    Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency Associated Liver Disease (ALPHATUDE)

  • IRAS ID

    359406

  • Contact name

    Tami Nussbaum

  • Contact email

    tami.nussbaum@takeda.com

  • Sponsor organisation

    Takeda Development Center Americas, Inc.

  • Clinicaltrials.gov Identifier

    NA, NA

  • Duration of Study in the UK

    6 years, 2 months, 16 days

  • Research summary

    Alpha-1 antitrypsin deficiency (AATD) is an inherited disorder potentially leading to liver and/or lung disease in adults and liver disease in children.
    The AATD is diagnosed through blood tests with confirmatory genetic testing. There is neither newborn screening nor an established patient identification algorithm for AATD. The optimal frequency of monitoring for AATD-liver disease also has not been formally established, as there is currently no widely adopted standard of care established for the monitoring or care of AATD-liver disease. As a result, liver disease in adults is often not diagnosed until cirrhosis or the development of Hepatocellular Carcinoma, with consequences on quality of life and healthcare costs.
    Healthcare resource utilization (HCRU), health-related quality of life (HRQoL), work productivity, and other patient-reported outcomes (PROs) through the AATD-liver disease continuum are important measures that will advance knowledge about the impact of disease and potentially provide insight on treatment needs and benefits. However, there are knowledge gaps regarding HCRU and PRO measures, and how they change as AATD-liver disease progresses. This prospective study aimed to bridge these knowledge gaps by providing follow-up of AATD patients and a more complete understanding of prospectively collected HCRU and PROs.
    Data on HRQoL, HCRU, work productivity, and other PROs will be collected from NHS patients at enrolment and throughout the duration of the study. All enrolled patients will be followed for changes in pulmonary function, lung disease development and/or lung disease progression.
    The total duration of the study to be a maximum of 8 years. Patients will be enrolled over a period of up to 3 years, or until the target sample size is achieved, whichever occurs first. Patients will be followed for a minimum of 4 years from enrollment or until loss to follow-up, withdrawal from the study, death or end of the study period.

  • REC name

    London - Harrow Research Ethics Committee

  • REC reference

    25/LO/0635

  • Date of REC Opinion

    18 Sep 2025

  • REC opinion

    Further Information Favourable Opinion